

October 23, 2017



# **Interpace Diagnostics Presents Important Data at the World Congress of Gastroenterology at American College of Gastroenterology (ACG) 2017**

## **Presentations on PancraGEN® and BarreGEN® Accepted by College**

PARSIPPANY, N.J., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ:IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, reported today that two publications were presented at the World Congress of Gastroenterology (WCOG) American College of Gastroenterology (ACG) 2017 Conference held October 16-18, 2017 in Orlando, Florida.

Dr. Mohammad Al-Haddad from the Department of Medicine at Indiana University Hospital in Indianapolis, Indiana, and Dr. Nadim Haddad, the Chief of the Division of Gastroenterology and Hepatology at MedStar Georgetown University Hospital, Washington, D.C., presented a study entitled "Long-Term Risk of Surgery and Cancer in Patients Meeting AGA 2015 and Fukuoka 2012 Management Criteria for Pancreatic Cystic Lesions." The study demonstrated that when PancraGEN® is used in a real world clinical setting, molecular results helped determine cancer risk in patients with pancreatic cysts that were worrisome but not definitively malignant. Importantly, the study showed that high risk molecular results increased necessary surgical resections of worrisome cysts by over 40%. Low-risk molecular results reduced unnecessary surgical resections of worrisome cysts by approximately 10%.

Dr. William Lyday of Gastroenterology Atlanta, LLC, formerly with Cancer Treatment Centers of America, presented a study entitled, "Regenerated Squamous Epithelium Following Radiofrequency Ablation Manifests Molecular Alterations Present in the Pretreated Barrett's Mucosa." The study demonstrated that patients who undergo successful ablation treatment for Barrett's Esophagus can have residual genomic mutations that linger; they can even develop new mutations that were not detectable prior to ablation. The results position BarreGEN®, Interpace's molecular test for Barrett's Esophagus, as a potential predictive biomarker that can help guide patient management after successful ablation treatment has taken place in patients with Barrett's disease.

"These publications, shared with the significant number of other physicians attending this prestigious conference, provided an opportunity for a broader understanding of the potential benefit that both PancraGEN and BarreGEN have for favorably impacting the diagnosis and treatment of patients with complicated gastroesophageal diseases such as pancreatic and esophageal cancer," stated Jack Stover, President and CEO of Interpace.

## **About PancraGEN**

PancraGEN® is a pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.

### **About BarreGEN**

Interpace Diagnostics' BarreGEN test utilizes the PathFinderTG® platform, which assesses loss of heterozygosity and microsatellite instability mutations of multiple tumor suppressor genes. BarreGEN summarizes this genomic instability information as the Mutational Load, enabling physicians to more accurately stratify patients with Barrett's esophagus for risk of progression to dysplasia and cancer. This can allow for more personalized management of the disease, including early intervention to decrease likelihood of the progression to cancer. All patients with Barrett's esophagus or those that have had radiofrequency ablation are potential candidates for testing with BarreGEN.

### **About the American College of Gastroenterology and ACG**

The American College of Gastroenterology is one of the largest specialty societies focused on diseases of the gastrointestinal tract. The College sponsors numerous educational meetings throughout the year for their members, including the Annual meeting, which brings together over 5,000 Gastroenterologists and other healthcare professionals to focus on diagnosing and treating a wide array of GI related illnesses.

### **About Interpace Diagnostics Group, Inc.**

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has four commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer utilizing a proprietary gene expression assay and MVPdX™, a test that differentiates local recurrence of cancer versus new primary cancer formation. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

### **Forward-Looking Statements**

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and*

*uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, its ability to restructure its liabilities and other obligations, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.*

*Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

#### CONTACTS:

Interpace Diagnostics  
Investor Relations:  
Paul Kuntz  
RedChip  
paul@redchip.com



Source: Interpace Diagnostics Group, Inc.